Monday, November 17, 2008

Press release from Celprogen Inc.

Celprogen Introduces an in vivo Model for Human Brain Cancer (Human Glioblastoma GBM) for Drug Discovery Applications, Business Wire, November 17, 2008. Excerpt:
Celprogen has established a Drug Discovery program to provide drug efficacy testing services to major Pharmaceutical firms for their potential drugs against Human Glioblastoma. The other in vivo cancer model systems in the pipe line at Celprogen are: breast cancer, prostate cancer, liver cancer, colon cancer, lung cancer and pancreatic cancer that are scheduled to be released as early as the beginning of second quarter 2009. These in vivo cancer model systems are being generated from already established Celprogen’s Cancer Stem Cells.
See also: Celprogen Launches Cancer Stem Cells, Medical News Today, January 25, 2008.

About Celprogen (located in San Pedro, California).

1 comment:

  1. A comment was received in which this question was asked: "Where is any of the peer reviewed data or Celprogen open source publications in a peer reviewed journal?". Answers to this question would be welcomed. --Editor